Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1970 1
1971 1
1972 3
1973 1
1981 1
1984 1
1985 1
1986 1
1987 2
1989 3
1990 1
1991 2
1992 2
1993 2
1994 1
1995 4
1996 8
1997 5
1998 2
1999 5
2000 4
2001 1
2002 2
2003 2
2004 5
2005 7
2006 5
2007 3
2008 7
2009 13
2010 12
2011 14
2012 21
2013 19
2014 23
2015 23
2016 18
2017 23
2018 34
2019 37
2020 24
2021 41
2022 39
2023 29
2024 44
2025 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

464 results

Results by year

Filters applied: . Clear all
Page 1
The IL-22-oncostatin M axis promotes intestinal inflammation and tumorigenesis.
Cineus R, Luo Y, Saliutina M, Manna S, Cancino CA, Velasco Blázquez L, Wang L, Bösel D, Abdelrahman A, Klementowicz JE, Scherl A, Hainbuch S, Bréart B, Kwon G, Konopka A, Guerra GM, von Coburg E, Gerbeth L, Roels J, Heinrich F, Müller N, Durek P, Deigendesch N, Ziai J, Hung J, Conrad T; TRR241 IBDome Consortium; Kühl AA, Wirtz S, Löhning M, Keir M, Diefenbach A, Mashreghi MF, Siegmund B, Schumann M, Romagnani C, West NR, Hegazy AN. Cineus R, et al. Among authors: schumann m. Nat Immunol. 2025 Jun;26(6):837-853. doi: 10.1038/s41590-025-02149-z. Epub 2025 May 30. Nat Immunol. 2025. PMID: 40447860 Free PMC article.
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. Schuppan D, et al. Among authors: schumann m. N Engl J Med. 2021 Jul 1;385(1):35-45. doi: 10.1056/NEJMoa2032441. N Engl J Med. 2021. PMID: 34192430 Free article. Clinical Trial.
Aktualisierte S2k-Leitlinie Zöliakie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
Felber J, Bläker H, Fischbach W, Koletzko S, Laaß M, Lachmann N, Lorenz P, Lynen P, Reese I, Scherf K, Schuppan D, Schumann M, Aust D, Baas S, Beisel S, de Laffolie J, Duba E, Holtmeier W, Lange L, Loddenkemper C, Moog G, Rath T, Roeb E, Rubin D, Stein J, Török H, Zopf Y. Felber J, et al. Among authors: schumann m. Z Gastroenterol. 2022 May;60(5):790-856. doi: 10.1055/a-1741-5946. Epub 2022 May 11. Z Gastroenterol. 2022. PMID: 35545109 Free article. German. No abstract available.
Guidelines for best practices in monitoring established coeliac disease in adult patients.
Elli L, Leffler D, Cellier C, Lebwohl B, Ciacci C, Schumann M, Lundin KEA, Chetcuti Zammit S, Sidhu R, Roncoroni L, Bai JC, Lee AR, Dennis M, Robert ME, Rostami K, Khater S, Comino I, Cebolla A, Branchi F, Verdu EF, Stefanolo JP, Wolf R, Bergman-Golden S, Trott N, Scudeller L, Zingone F, Scaramella L, Sanders DS. Elli L, et al. Among authors: schumann m. Nat Rev Gastroenterol Hepatol. 2024 Mar;21(3):198-215. doi: 10.1038/s41575-023-00872-2. Epub 2023 Dec 18. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38110546 Review.
Reply.
Dieckman T, Schumann M, Beaumont H, Bontkes HJ, Koning F, Bouma G; RCDII Tofacitinib Consortium. Dieckman T, et al. Among authors: schumann m. Clin Gastroenterol Hepatol. 2025 Mar;23(4):679-680. doi: 10.1016/j.cgh.2024.08.045. Epub 2024 Oct 19. Clin Gastroenterol Hepatol. 2025. PMID: 39427853 No abstract available.
IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption.
Langer V, Vivi E, Regensburger D, Winkler TH, Waldner MJ, Rath T, Schmid B, Skottke L, Lee S, Jeon NL, Wohlfahrt T, Kramer V, Tripal P, Schumann M, Kersting S, Handtrack C, Geppert CI, Suchowski K, Adams RH, Becker C, Ramming A, Naschberger E, Britzen-Laurent N, Stürzl M. Langer V, et al. Among authors: schumann m. J Clin Invest. 2019 Nov 1;129(11):4691-4707. doi: 10.1172/JCI124884. J Clin Invest. 2019. PMID: 31566580 Free PMC article. Clinical Trial.
ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo.
Schulz-Kuhnt A, Rühle K, Javidmehr A, Döbrönti M, Biwank J, Knittel S, Neidlinger P, Leupold J, Liu LJ, Dedden M, Taudte RV, Gessner A, Fromm MF, Mielenz D, Kreiss L, Waldner MJ, Schürmann S, Friedrich O, Dietel B, López-Posadas R, Plattner C; TRR241 IBDome Consortium; Zundler S, Becker C, Atreya R, Neurath MF, Atreya I. Schulz-Kuhnt A, et al. Gut. 2024 Mar 7;73(4):601-612. doi: 10.1136/gutjnl-2023-330543. Gut. 2024. PMID: 38176897
464 results